Magdalena Chechlinska

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/545136/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Prognostic Value of the Immunological Subtypes of Adolescent and Adult T-Cell Lymphoblastic Lymphoma; an Ultra-High-Risk Pro-T/CD2(â^) Subtype. Cancers, 2021, 13, 1911.	3.7	2
2	A Set of 17 microRNAs Common for Brain and Cerebrospinal Fluid Differentiates Primary Central Nervous System Lymphoma from Non-Malignant Brain Tumors. Biomolecules, 2021, 11, 1395.	4.0	3
3	Genes, pathways and vulvar carcinoma - New insights from next-generation sequencing studies. Gynecologic Oncology, 2020, 158, 498-506.	1.4	15
4	Tumor and Cerebrospinal Fluid microRNAs in Primary Central Nervous System Lymphomas. Cancers, 2019, 11, 1647.	3.7	14
5	A comprehensive flow-cytometry-based immunophenotypic characterization of Burkitt-like lymphoma with 11q aberration. Modern Pathology, 2018, 31, 732-743.	5.5	42
6	<i>Tumor Biology</i> : A new chapter. Tumor Biology, 2018, 40, 101042831774881.	1.8	1
7	Technetium-99m-based Radiopharmaceuticals in Sentinel Lymph Node Biopsy: Gynecologic Oncology Perspective. Current Pharmaceutical Design, 2018, 24, 1652-1675.	1.9	7
8	Changes in plasma miR-9, miR-16, miR-205 and miR-486 levels after non-small cell lung cancer resection. Cellular Oncology (Dordrecht), 2017, 40, 529-536.	4.4	58
9	Analysis of Newly Identified and Rare Synonymous Genetic Variants in the RET Gene in Patients with Medullary Thyroid Carcinoma in Polish Population. Endocrine Pathology, 2017, 28, 198-206.	9.0	3
10	DA-EPOCH-R Is an Effective Regimenin High Grade B-Cell Lymphoma Defined By Cell-of-Origin, Karyotype and BCL2/MYC/BCL6 Status and Expression. Blood, 2016, 128, 1754-1754.	1.4	2
11	miR expression in MYC-negative DLBCL/BL with partial trisomy 11 is similar to classical Burkitt lymphoma and different from diffuse large B–cell lymphoma. Tumor Biology, 2015, 36, 5377-5388.	1.8	17
12	Significance of a Critical Set of 11q Chromosome Aberrations for Diagnosis of MYC Negative Burkitt Lymphoma. Blood, 2015, 126, 2679-2679.	1.4	1
13	miR-7 expression in serous ovarian carcinomas. Anticancer Research, 2015, 35, 2423-9.	1.1	5
14	Gene expression profiling of peripheral blood cells: new insights into Ewing sarcoma biology and clinical applications. Medical Oncology, 2014, 31, 109.	2.5	19
15	microRNAs in uterine sarcomas and mixed epithelial–mesenchymal uterine tumors: a preliminary report. Tumor Biology, 2013, 34, 2153-2160.	1.8	28
16	Serum macrophage colony-stimulating factor (M-CSF) in patients with Hodgkin lymphoma. Medical Oncology, 2012, 29, 2143-2147.	2.5	14
17	Discriminant analysis involving serum cytokine levels and prediction of the response to therapy of patients with Hodgkin lymphoma. Tumor Biology, 2012, 33, 1733-1738.	1.8	7
18	A survey of prognostic value of serum factors in multiple myeloma patients before treatment: macrophage-colony stimulating factor (M-CSF) is a powerful predictor of survival. Medical Oncology, 2011, 28, 194-198.	2.5	7

#	Article	IF	CITATIONS
19	Squamous cell carcinoma antigen 1 and 2 expression in cultured normal peripheral blood mononuclear cells and in vulvar squamous cell carcinoma. Tumor Biology, 2010, 31, 559-567.	1.8	19
20	Implications of cancer-associated systemic inflammation for biomarker studies. Biochimica Et Biophysica Acta: Reviews on Cancer, 2010, 1806, 163-171.	7.4	15
21	Procollagen I amino-terminal propeptide as a potential marker for multiple myeloma. Clinical Biochemistry, 2010, 43, 604-608.	1.9	9
22	Systemic inflammation as a confounding factor in cancer biomarker discovery and validation. Nature Reviews Cancer, 2010, 10, 2-3.	28.4	136
23	Serum soluble tumour necrosis factor receptor type I concentrations independently predict prognosis in patients with breast cancer. Clinical Chemistry and Laboratory Medicine, 2010, 48, 1481-6.	2.3	16
24	Molecular signature of cell cycle exit induced in human T lymphoblasts by IL-2 withdrawal. BMC Genomics, 2009, 10, 261.	2.8	17
25	The sensitivity of BRCA1 mutation carriers to ionising radiation: questions of methodology. Breast Cancer Research and Treatment, 2009, 115, 433-433.	2.5	1
26	Carcinoembryonic antigen and cytokeratin 20 in peritoneal cells of cancer patients: are we aware of what we are detecting by mRNA examination?. British Journal of Cancer, 2008, 98, 512-513.	6.4	16
27	Cytokines as potential tumour markers. Expert Opinion on Medical Diagnostics, 2008, 2, 691-711.	1.6	13
28	Critical Involvement of the ATM-Dependent DNA Damage Response in the Apoptotic Demise of HIV-1-Elicited Syncytia. PLoS ONE, 2008, 3, e2458.	2.5	41
29	Peritoneal fluid cytokines and the differential diagnosis of benign and malignant ovarian tumors and residual/recurrent disease examination. International Journal of Biological Markers, 2007, 22, 172-180.	1.8	8
30	Pretreatment Serum Levels of Cytokines and Cytokine Receptors in Patients with Non-Small Cell Lung Cancer, and Correlations with Clinicopathological Features and Prognosis. Oncology, 2006, 70, 115-125.	1.9	111
31	The relevance of RT-PCR detection of disseminated tumour cells is hampered by the expression of markers regarded as tumour-specific in activated lymphocytes. European Journal of Cancer, 2006, 42, 2671-2674.	2.8	45
32	The relevance of RT–PCR markers for metastatic tumour cell detection. British Journal of Cancer, 2006, 94, 1761-1761.	6.4	1
33	Clinical Significance of Serum Cytokine Measurements in Untreated Colorectal Cancer Patients: Soluble Tumor Necrosis Factor Receptor Type I – An Independent Prognostic Factor. Tumor Biology, 2005, 26, 186-194.	1.8	89
34	Sera of lung cancer patients affect the release of Th1, Th2 and monocyte-derived cytokines, and the expression of IL-2Ralpha by normal, stimulated mononuclear cells. Cellular and Molecular Biology Letters, 2004, 9, 69-81.	7.0	7
35	Telomere shortening and atherosclerosis. Lancet, The, 2002, 359, 976.	13.7	8